Search
Enprostil
go.drugbank.com/drugs/DB13824ExperimentalCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)CDX-1135
go.drugbank.com/drugs/DB17607InvestigationalIt was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage. … CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalDeveloped by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
Fiztasovimab
go.drugbank.com/drugs/DB24033Investigational[A278004, A278005] NPC-21 is under investigation in clinical trial NCT04225923 (A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection).
AEOL-10150
go.drugbank.com/drugs/DB05874ExperimentalAEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Albuvirtide
go.drugbank.com/drugs/DB15166InvestigationalAlbuvirtide is under investigation in clinical trial NCT03719664 (Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects).
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseXL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation
SBT-100
go.drugbank.com/drugs/DB17215ExperimentalIt was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Masofaniten
go.drugbank.com/drugs/DB21580InvestigationalMasofaniten is under investigation in clinical trial NCT06312670 (Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer).
Verubecestat
go.drugbank.com/drugs/DB12285InvestigationalIn July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. … Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment.